Share Prices & Company Research

Market News

31 Aug 2021 | 07:02

GSK, SK Bioscience to start Phase 3 Covid vaccine trial

(Sharecast News) - South Korea's SK Bioscience and the UK's GlaxoSmithKline on Tuesday said they would start a phase 3 clinical study of SK's Covid-19 vaccine candidate combined with GSK's pandemic vaccine booster The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to evaluate GBP510's safety and immunogenicity compared to the AstraZeneca/Oxford University Covid-19 vaccine.

Results from the late-stage study are expected in the first half of 2022 after which the vaccine is expected to be supplied at scale worldwide through the COVAX facility, the two companies said in a statement.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.